Sellas Life Sciences Group Inc (SLS)

NASDAQ
2.96
+0.06(+2.07%)
After Hours
3.10
+0.14(+4.73%)
- Real-time Data
  • Volume:
    108,861
  • Day's Range:
    2.83 - 2.99
  • 52 wk Range:
    2.10 - 15.08

SLS Overview

Prev. Close
2.9
Day's Range
2.83-2.99
Revenue
2.9M
Open
2.9
52 wk Range
2.1-15.08
EPS
-2.22
Volume
108,861
Market Cap
60.79M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
284,235
P/E Ratio
-
Beta
1.66
1-Year Change
-71.68%
Shares Outstanding
20,535,629
Next Earnings Date
Aug 18, 2022
What is your sentiment on Sellas Life Sciences?
or
Market is currently closed. Voting is open during market hours.

Sellas Life Sciences Group Inc News

Sellas Life Sciences Group Inc Analysis

Sellas Life Sciences Group Inc Company Profile

Sellas Life Sciences Group Inc Company Profile

Employees
7

SELLAS Life Sciences Group, Inc. is a biopharmaceutical company that is focused on developing cancer immunotherapeutics for a range of cancer indications. The Company’s product candidates include galinpepimut-S and nelipepimut-S. Its lead product candidate, galinpepimut-S is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center that targets a spectrum of hematologic cancers and solid tumor indications. Its nelipepimut-S is a cancer immunotherapy targeting the human epidermal growth factor receptor 2 (HER2), which is expressing cancers with potential for the treatment of patients with early-stage breast cancer with low to intermediate HER2 expression, which includes triple negative breast cancer (TNBC) patients.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyNeutralNeutralStrong SellStrong Sell
Technical IndicatorsStrong BuyStrong BuyStrong SellBuyStrong Sell
SummaryStrong BuyBuySellNeutralStrong Sell
  • gains
    0
    • cannot see it on its chart
      0
  • To clarify, this is a report for alignant pleural mesothelioma (MPM). which is in the first stageThe report for Acute Myeloid Leukemia (AML) which is in the third phase is coming out by the end of June. you have to wait, for now everything is ok
    1
    • Updated Data Show Median Overall Survival of 35.4 Weeks in Patients Treated With Combination Therapy for at Least One Month – Median Overall Survival in Relapse/Refractory Patients with Standard of Care is Approximately 28 weeksNew and Updated Clinical and Translational Data Expected by End of Q4 2021NEW YORK, June 24, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today announced encouraging updated clinical data from a Phase 1 investigator-sponsored clinical trial of its lead clinical candidate, galinpepimut-S (GPS), combined with the checkpoint inhibitor nivolumab (Opdivo®) in patients with macroscopic (measurable) deposits of malignant pleural mesothelioma (MPM).
      0
      • very good test results
        0
        • 👍👍
          0
          • soon going to 30-50
            0
            • Russel microcap index add.... Good...
              0
              • Been in this from $2 21000shares I believe life changer
                0
                • oll
                  0
                  • https://www.sellaslifesciences.com/investors/news/News-Details/2021/SELLAS-Life-Sciences-Announces-USPTO-Decision-to-Grant-New-Patent-for-Galinpepimut-S-in-Combination-with-Checkpoint-Inhibitor-Therapies/default.aspx
                    0